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Abstract
Background:  To investigate the clinical differences between pulse wave velocity and
augmentation index in diabetic retinopathy.
Methods: The subjects were 201 patients with type 2 diabetes. These subjects were measured for
both augmentation index (AI) and brachial-ankle pulse wave velocity (baPWV) by a pulse wave
analyzer. The relationships between AI, baPWV, and diabetic retinopathy were examined.
Results: BaPWV was significantly higher in patients with diabetic retinopathy than in individuals
without the disease. (20.13 ± 3.66 vs.17.14 ± 3.60 m/s p < 0.001) AI was higher in patients with
diabetic retinopathy, but not significantly. (19.5 ± 15.2 vs. 14.8 ± 20.5% p = 0.14) The association
between baPWV and diabetic retinopathy remained statistically significant after adjustment. (Odds
ratio: 1.21 Per m/s, 95% confidence interval: 1.07–1.37) On the other hand, the association
between AI and diabetic retinopathy was not statistically significant. (Odds ratio: 1.01 Per %, 95%
confidence interval: 0.98–1.03)
Conclusion: BaPWV is associated with diabetic retinopathy, but AI is not. The clinical significance
appears to be different between PWV and AI in patients with diabetes.
Background
Both pulse wave velocity (PWV) and augmentation index
(AI) are known as markers of arterial stiffness [1]. These
parameters have been associated with cardiovascular dis-
ease. The definition and measurement of these parameters
is different, therefore, the clinical significance may also be
different. PWV was defined as the speed with which the
pulse wave travels along the length of an artery. Augmen-
tation of the pulse waveform was defined as the difference
between the second systolic peak (caused by wave reflec-
tion) and the first systolic peak (caused by left ventricular
ejection). AI was this difference expressed as a percentage
of the central pulse pressure. It is reported that type 2 dia-
betes is associated with increased AI, and decreased
carotid-femoral transit time, which is related to PWV [2].
On the other hand, it has been reported that there is no
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association between AI and PWV in patients with diabetes
[3]. Thus, the clinical difference between PWV and AI
remains uncertain in patients with diabetes. We previ-
ously reported an association between diabetic retinopa-
thy and brachial-ankle pulse wave velocity (baPWV) [4].
However, we did not investigate the relationship between
AI and diabetic retinopathy. In this study, to clarify the
clinical difference between PWV and AI, we investigated
the association between baPWV, AI and diabetic retinop-
athy.
Methods
Japanese patients with type 2 diabetes who had randomly
undergone testing for both baPWV and AI of the common
carotid artery between April 2002 and April 2003 at the
outpatient department of the Juntendo University Hospi-
tal (Tokyo, Japan) were enrolled in this study. Informed
consent was obtained from all subjects. Clinical data were
collected in a cross sectional manner from medical
records. Type 2 diabetes was indicated by a fasting plasma
glucose concentration >7.0 mmol/L without treatment, a
plasma glucose concentration 11.0 mmol/L measured 2 h
after a 75 g oral glucose load, or by treatment with a glu-
cose-lowering drug. The patients selected for the study
were in a state of sinus rhythm. The patients selected for
the study had no history of ketoacidosis, ischemic heart
disease, peripheral artery disease or ischemic stroke.
Patients with an ankle-brachial pressure index (ABI) <0.9
were excluded from the analysis. Diagnoses of diabetic
retinopathy were made by ophthalmologists based on the
presence of one or more of the following clinical features
in the fundus: hemorrhages, hard or soft exudate, venous
beading, intra-retinal microvascular abnormalities, cot-
ton-wool spots, pre-retinal new vessels, fibrous prolifera-
tion and/or photocoagulation scars. Diabetic
nephropathy was defined as a casual urinary albumin/cre-
atinine ratio >30 mg/g Cr. Total cholesterol, high-density
lipoprotein (HDL) cholesterol, triglyceride and hemo-
globin A1c (HbA1c), urinary albumin and creatinine lev-
els were determined using standard laboratory
techniques.
Measurements of PWV and AI
Measurement of baPWV and AI were performed on the
same day. The automatic pulse wave analyzer (Form/ABI
with AT-unit; Omron Colin Co. Ltd, Tokyo) was used to
measure baPWV, AI and ABI. This device has been
approved by the US food and drug administration. The
device simultaneously performs an electrocardiogram,
phonocardiogram, bilateral brachial and ankle blood
pressure (BP), and carotid arterial pulse wave. The
detailed method to measure baPWV and ABI was previ-
ously reported [5,6]. Briefly, measurement was performed
with the patients in the supine position after resting for
five minutes. Occlusion and monitoring cuffs were placed
snugly around sites in the upper and lower extremities.
Pressure waveforms were then recorded simultaneously
from the brachial arteries by an oscillometric method. The
ABI was calculated as follows: ABI = ankle systolic BP/bra-
chial systolic BP. It is well known that patients with a low
ABI exhibit a lower baPWV value than the actual value
when assessed by the method described above [7]. Thus,
we excluded patients with an ABI level of less than 0.9
when evaluating baPWV.
Carotid arterial pulse wave were obtained using arterial
applanation tonometry incorporating an array of 15
micropiezoresistive transducers. Advanced multiplexing
electronics combined with automatic sensor selection rel-
ative to the target artery facilitated and ensured optional
placement of the sensor. The carotid sensor was manually
placed on the common carotid artery. The systolic portion
of the central arterial waveform is characterized by two
pressure peaks. The first peak is caused by left ventricular
ejection, whereas the second peak is a result of wave
reflection. The difference between both pressure peaks
reflects the degree to which central arterial pressure is aug-
mented by wave reflection. The AI (%) is defined as the
percentage of the central pulse pressure which is repre-
sented by the reflected pulse wave and, therefore, reflects
the degree to which central arterial pressure is augmented
by wave reflection [8]. The reliability and reproducibility
of the AI measured by this device are reported to be very
good [9,10]. These measurements were taken with
patients lying in a supine position after 5 min of rest.
Statistical analysis
In order to compare the association between baPWV and
diabetic retinopathy, and between AI and diabetic retin-
opathy, we performed several statistical analyses. First,
subjects were divided into two groups: those with and
those without diabetic retinopathy. Clinical characteris-
tics, including baPWV and AI, were analyzed within the
two groups. Continuous variables were presented as the
mean standard deviation (S.D.). Continuous variables
were compared using Student's t-test and categorical data
were compared using the chi-squared test. Second, we
used linear regression analysis to investigate the correla-
tion between baPWV and AI. Third, multiple regression
analysis was performed to investigate the relationship
between arterial stiffness markers and clinical parameters.
Multiple logistic-regression analysis was used to provide
the adjusted odds ratios (ORs) for baPWV and AI for dia-
betic retinopathy. The following factors were adjusted for:
age, gender, duration of diabetes, HbA1c level, diabetic
nephropathy, hypertension (systolic BP > 140 mmHg
and/or diastolic BP > 90 mmHg) and hyperlipidemia
(total cholesterol concentration > 5.7 mmol/L and/or trig-
lyceride concentration >1.7 mmol/L and/or treatment
with antihyperlipidemic agents). In addition, AI wasCardiovascular Diabetology 2008, 7:11 http://www.cardiab.com/content/7/1/11
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increasing more in younger individuals [11,12]. There-
fore, the subjects were divided into two groups, under 60
years old and over 60 years old. We analyzed relationship
between AI and retinopathy each groups. The ORs are pre-
sented with 95% confidence intervals (CIs). All statistical
analyses were performed using StatView version 5.0 com-
puter software (SAS Institute Inc. Cary, NC, USA). Proba-
bility values (p) < 0.05 were considered statistically
significant.
Results
The presence of diabetic retinopathy was confirmed in 47
(23.4%) of the 201 patients who were eligible to take part
in the study. Table 1 shows the characteristics of the sub-
jects according to the presence or absence of diabetic
retinopathy. BaPWV, duration of diabetes, body height,
heart rate, systolic BP and total cholesterol were all signif-
icantly higher in patients with diabetic retinopathy than
in individuals without the disease. The proportion of
female patients, presence of nephropathy and use of anti-
hypertensive agents were also higher among those with
diabetic retinopathy. AI was higher in patients with dia-
betic retinopathy, but not statistically significant. On lin-
ear regression analysis, the correlation between baPWV
and AI was weak (r = 0.19, p = 0.007).
On the multiple regression analysis, age, duration, heart
rate, and SBP were dependent determinants of baPWV,
while age, height, heart rate, and DBP were independent
determinants of AI. (table 2)
The results of the logistic regression analyses are shown in
table 3. The association between baPWV and diabetic
retinopathy remained statistically significant after adjust-
ment. On the other hand, the association between AI and
diabetic retinopathy was not statistically significant. Dura-
tion, diabetic nephropathy were also significantly associ-
ated with diabetic retinopathy after adjustment. ORs of AI
in group over 60 years old was 1.00 (95%CI 0.97–1.04),
odds ratio of AI in group under 60 years old was 1.00
(95%CI 0.97–1.05) after adjusted age, gender, duration of
diabetes, HbA1c, hypertension, hyperlipidemia, nephrop-
athy.
Discussion
In this study, there was a significant positive association
between the presence of diabetic retinopathy and baPWV
among Japanese type 2 diabetic patients without mac-
roangiopathy. However, the association between AI and
diabetic retinopathy was found to be uncertain. The corre-
lation between baPWV and AI was weak. The determining
factors were different between baPWV and AI.
Previously, we showed baPWV is associated with diabetic
retinopathy [4]. PWV is correlated with the duration of
diabetes and with the accumulation of fluorescent
advanced glycation end products in the aorta[13]. The
accumulation of advanced glycation end products has
Table 1: Characteristics of the 201 patients enrolled in the study according to the presence (+) or absence (-) of diabetic retinopathy.
DR(+) n = 47 DR(-) n = 154 P value
baPWV (m/s) 20.13 ± 3.66 17.14 ± 3.60 <0.001
AI (%) 19.5 ± 15.2 14.8 ± 20.4 0.14
Height (m) 1.59 ± 0.08 1.63 ± 0.08 0.003
Age (years) 61.1 ± 10.6 59.7 ± 11.2 0.44
Men (n) 25 (53%) 110 (71%) 0.03
Duration (years) 13.0 ± 8.5 8.6 ± 7.5 <0.001
Systolic BP (mmHg) 142.7 ± 16.3 129.3 ± 17.9 <0.001
Diastolic BP (mmHg) 82.8 ± 11.1 78.3 ± 9.56 0.007
Heart rate (beat/min) 72.4 ± 12.0 66.3 ± 10.5 0.001
HbA1c (%) 7.2 ± 1.5 7.4 ± 1.9 0.56
Total cholesterol (mmol/L) 5.88 ± 2.74 5.14 ± 0.89 0.004
HDL cholesterol (mmol/L) 1.40 ± 0.47 1.31 ± 0.40 0.22
Triglycerides (mmol/L) 1.68 ± 0.88 1.74 ± 1.12 0.75
Nephropathy 27 (18%) 27 (57%) <0.001
Antihypertensive agents (yes/no) 129/150 251/629 <0.001
Mean values are indicated ± the standard deviation. DR, diabetic retinopathy.
Table 2: multiple regression analysis of baPWV and AI
BaPWV AI
rprp
Age 0.37 <0.001 0.29 <0.001
Height -0.04 0.50 -0.31 <0.001
SBP 0.50 <0.001 0.02 0.86
DBP -0.16 0.06 0.26 0.01
Heart rate 0.25 <0.001 -0.40 <0.001
Duration 0.12 0.02 -0.03 0.61
HbA1c 0.02 0.74 -0.05 0.41
Correlation coefficients of multiple regression (r) and the level of 
significance are shown.Cardiovascular Diabetology 2008, 7:11 http://www.cardiab.com/content/7/1/11
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also been associated with the progression of diabetic
retinopathy [14,15]. Furthermore, the United Kingdom
Prospective Diabetes Study (UKPDS) showed that the
development of retinopathy was associated with long-
term glycemic exposure [16,17]. These findings indicate
that the common mechanism of arterial stiffness and
retinopathy might be the accumulation of advanced glyca-
tion end products due to chronic glycemic exposure. The
result of the association of other factors and diabetic retin-
opathy found in this study was similar with that which we
have previously reported. HbA1c and hypertension were
not significantly associated with diabetic retinopathy.
UKPDS showed the development of retinopathy to be
associated with long-term glycemic exposure and hyper-
tension [16-18]. The duration of diabetes was found to be
associated with diabetic retinopathy in this study. How-
ever, HbA1c is a marker for short-term glycemic control (1
or 2 months) only; thus the effects of glycemic control on
diabetic retinopathy might, therefore, not be evident in
this study. In addition, BP was not measured before the
onset of diabetic retinopathy in our study, so the effects of
hypertension might not be apparent. These results could
be a consequence of the cross-sectional study design.
The duration of diabetes determined baPWV, but not AI,
in this study. In addition, PWV was increased in patients
with diabetes, but this is not associated with AI [3]. In this
study, the correlation between baPWV and AI was weak.
These results indicated that chronic hyperglycemia
maynot be associated with increasing AI. On the other
hand, diabetic retinopathy is associated with chronic
hyperglycemia. Therefore, the result that AI was not asso-
ciated with diabetic retinopathy in this study may be due
to AI not being associated with the duration of diabetes.
AI was correlated with height, heart rate, SBP. On the
other hand, baPWV was correlated with age, SBP, and
heart rate [10]. In addition, AI was influenced by vasoac-
tive drugs independently of PWV [19]. Thus, baPWV and
AI were not interchangeable as markers of arterial stiff-
ness. AI has stronger potential for use in endothelial func-
tion testing rather than as a marker of arterial stiffness
compared with PWV [1]. These differences between PWV
and AI may have includend the results of the study.
Insulin sensitivity reportedly influences AI [20], but was
not examined in this study. Differences in insulin sensitiv-
ity may influenced the result of this study. PWV and AI are
both strongly related to age, but the age-related changes in
PWV and AI are non linear, with AI increasing more in
younger individuals [11,12]. The age of the patients in
study was not as advanced. These factors may be affected
the result of our study.
A positive association between AI and diabetic retinopa-
thy has been previously reported [21]. In that study, sub-
jects with macroangiopathy were included. Diabetic
retinopathy is also reportedly associated with cardiovas-
cular disease [22]. Both AI and PWV are also associated
with macroangiopathy [23,24]. These associations may
have influenced the reported result. In this study, to avoid
the association between arterial stiffness and macroangio-
pathy, patients with macroangiopathy were excluded. In
addition, data of height and heart rate were not included.
Height and heart rate are reportedly associated with PWV
and AI [10], so these unincorporated data may have influ-
enced their result. Another possibility is that the devices in
each study were different. A well-designed study will be
needed to clearly elucidate the association between AI and
diabetic retinopathy, and to identify the relevant features
with utility for clinical practice.
Table 3: Adjusted odds ratios for diabetic retinopathy
Independent variable Adjusted odds ratio (95% CI) p Adjusted odds ratio (95% CI) p
Age Per year 0.95(0.91–0.99) 0.02 0.97(0.94–1.05) 0.21
Sex Female 1.00 1.00
Male 0.33 (0.14–0.78) 0.01 0.37 (0.16–0.88) 0.02
Duration of diabetes (per year) 1.06 (1.004–1.11) 0.03 1.07 (1.02–1.12) 0.01
HbA1c Per % 0.96(0.75–1.21) 0.7 0.97(0.77–1.21) 0.75
Hypertension No 1.00 1.00
Yes 1.37 (0.59–3.19) 0.47 1.91 (0.86–4.28) 0.11
Hyperlipidemia no 1.00 1.00
yes 0.96 (0.42–2.18) 0.91 0.90 (0.41–1.99) 0.80
Diabetic nephropathy No 1.00 1.00
yes 4.57 (2.04–10.28) <0.001 5.24 (2.40–11.4) <0.001
baPWV Per m/s 1.21(1.07–1.37) 0.002 -
AI Per % - 1.01(0.98–1.03) 0.65
Diabetic retinopathy was used as dependent variable., CI: confidence intervalPublish with BioMed Central    and   every 
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Conclusion
PWV and AI are reported markers of arterial stiffness, but
differing results have been obtained for diabetic retinopa-
thy. The clinical significance of PWV and AI appears to be
different in patients with diabetes.
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